MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Tessitore, Alessandra ^a   Cicciarelli, Germana ^a   Del Vecchio, Filippo ^a   Gaggiano, Agata ^a   Verzella, Daniela ^a   Fischietti, Mariafausta ^a   Mastroiaco, Valentina ^a   Vetuschi, Antonella ^a   Sferra, Roberta ^a   Barnabei, Remo ^b   Capece, Daria ^a   Zazzeroni, Francesca ^a   Alesse, Edoardo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

Author keywords

HCC; High fat diet; Low fat diet; MicroRNA; NAFLD; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 340 5P; MICRORNA 484; MICRORNA 574 3P; MICRORNA 720; UNCLASSIFIED DRUG; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL DENSITY; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HEPATOMEGALY; HISTOLOGY; LIPID DIET; LIPID STORAGE; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; LYMPHOCYTE; MACROPHAGE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLASMA CELL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES;

EID: 84959082381     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-2007-1     Document Type: Article

References (98)

1. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753-70.
2. Cramp ME. HBV+HCV+=+HCC? Gut. 1999;45(2):168-9.
3. Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, De Benedetti VM, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis. 1996;17(5):1007-12.
4. Tsukuma H, Hiyama T, Oshima A, Sobue T, Fujimoto I, Kasugai H, et al. A case-control study of hepatocellular carcinoma in Osaka, Japan. Int J Cancer. 1990;45(2):231-6.
5. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323-31.
6. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87(2):227-47.
7. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old question and new insights. Science. 2011;332(6037):1591-23.
8. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-65.
9. Bartel DP. MIcroRNAs: genomics, biogenesis, mechanism and function. Cell. 2004;116(2):281-97.
10. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287-314.
11. Sidhu K, Kapoor NR, Pandey V, Kumar V. The "macro" world of MicroRNAs in hepatocellular carcinoma. Front Oncol. 2015;5:68.
12. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12(6A):2189-204.
13. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014;2014:486407.
14. Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23(6PtB):471-82.
15. Gori M, Arciello M, Balsano C. MicroRNAs in non-alcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465.
16. Surwit RS, Van Tilburg MA, Parekh PI, Lane JD, Feinglos MN. Treatment regimen determines the relationship between depression and glycemic control. Diabetes Res Clin Pract. 2005;69(1):78-80.
17. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet. 2009;18:2975-88.
18. Chen Y, Yang C, Chang S, Hu M. C/EBP beta and C/EBP delta expression is elevated in the early phase of ethanol-induced hepatosteatosis in mice. Acta Pharmacol Sin. 2009;30:1138-43.
19. Frauloub JC, Ogg-Diamantino R, Fernandes-Santos C, Barbosa Aguila M, Mandarim-de-Larceda C. A mouse model of metabolic syndrome; insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFDP) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr. 2010;46:212-23.
20. Yang XW, Shen GZ, Cao LQ, Jiang XF, Peng HP, Shen G, et al. MicroRNA-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of FOXO1. BMC Cancer. 2014;14:909.
21. McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004;34(1):67-79.
22. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754.
23. Lydatakis H, Hager P, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 2006;26(7):864-71.
24. Bertino G, Ardiri M, Malguarnera M, Malguarnera N, Bertino N, Calvagno GS. Hepatocellular carcinoma serum markers. Semin Oncol. 2012;39(4):410-33.
25. Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010;16(35):4410-5.
26. Singhal A, Jayaraman M, Dhanasekaran N, Kholi V. Molecular and Serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol. 2012;82(2):116-40.
27. Nagoshi S. Osteopontin: versatile modulator of liver diseases. Hepatol Res. 2013;44(1):22-30.
28. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Parm Des. 2013;19(29):5169-76.
29. Dekker MJ, Su Q, Baker C, Rutledge AC, Adeli K. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2010;299:E685-94.
30. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of non-alcoholic fatty liver disease. J Nutr Biochem. 2012;23(3):203-8.
31. Longato L. Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair. 2013;6(1):14.
32. Schultz A, Barbosa-da-Silva S, Aquila MB, Mandarim-de-Lacerda CA. Diffences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed rich in fructose or sucrose. Food Funct. 2015;6(5):1684-91.
33. Miller AM, Gilchrist DS, Nijjar J, Araldi E, Ramirez CM, Lavery CA, et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One. 2013;8(8):e72324.
34. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, Rusyn I, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest. 2010;90:1437-46.
35. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of miR-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid defined diet in C57BL/6 mice. Hepatology. 2009;50:1152-61.
36. Csak T, Bala S, Lippai D, Kodys K, Catalano D, Iracheta-Vellve A, et al. MicroRNA-155 Deficiency Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis. Plos One. 2015;10:e0129251.
37. Zhang M, Zhou X, Wang B, Yung BC, Lee LJ, Ghoshal K, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. Control Release. 2013;168:251-61.
38. Chen J, Feilotter HE, Pare' GC, Zhang X, Pemberton JGW, Garady C, et al. MicroRNA-193b represses cell proliferation and regulates cyclin d1 in melanoma. Am J Pathol. 2010;176:2520-9.
39. Li HF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene. 2009;28:3937-48.
40. Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. 2014;35:76-85.
41. Yang Z, He M, Wang K, Sun G, Tang L, Xu Z. Tumor suppressive microRNA-193b promotes breast cancer progression via targeting DNAJC13 and RAB22A. Int J Clin Exp Pathol. 2014;7:7563-70.
42. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer. 2010;127(6):1363-72.
43. Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010;46(15):2828-36.
44. Waller-Evans H, Hue C, Fearnside J, Rothwell AR, Lockstone HE, Caldérari S, et al. Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome. PLoS One. 2013;8(12):e82825.
45. Braconi C, Valeri N, Gasparini P, Huang N, Taccioli C, Nuovo G, et al. Hepatitis C Virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res. 2010;16(3):957-66.
46. Lenarduzzi M, Hui A, Alajez NM, Shi W, Williams J, Yue S, et al. MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS One. 2013;8(1):e53765.
47. Zhong Q, Wang T, Lu P, Zhang R, Zou J, Yuan S. MiR-193b promotes cell proliferation by targeting smad3 in human glioma. J Neurosci Res. 2014;92:619-26.
48. Yang YA, Zhang GM, Feigenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell. 2006;9:445-57.
49. Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L. Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32(1):21.
50. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014;344:166-73.
51. Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR, Fu JF. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem. 2014;34:1983-97.
52. Dhayat SA, Mardin WA, Kohler G, Bahde R, Vowinkel T, Wolters H, et al. The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol. 2014;110:430-8.
53. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of MicroRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013;52:297-303.
54. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012;56:1792-803.
55. Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. MiR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:885-9.
56. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, et al. Upregulation of miR-23a+~+27a+~+24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 2008;123:972-8.
57. He XX, Kuang SZ, Liao JZ, Xu CR, Chang Y, Wu YL, et al. The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma. Mol Biosyst. 2015;11:532-9.
58. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol. 2013;87:5270-86.
59. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. 2009;583:759-66.
60. Hu J, Chen C, Liu Q, Liu B, Song C, Zhu S, et al. The role of the miR-31/FIH1 pathway in TGF-β-induced liver fibrosis. Clin Sci (Lond). 2015;129:305-17.
61. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264-9.
62. Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, et al. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015;6:3211-24.
63. Xiao ZG, Deng ZS, Zhang YD, Zhang Y, Huang ZC. Clinical significance of microRNA-93 downregulation in human colon cancer. Eur J Gastroenterol Hepatol. 2013;25(3):296-301.
64. Tang Q, Zou Z, Zou C, Zhang Q, Huang R, Guan X, et al. Micro-RNA-93 suppresses colorectal cancer development via Wnt/β-Catenin pathway downregulation. Tumor Biol. 2015;36(3):1701-10.
65. Wei F, Liu Y, Guo Y, Xiang A, Wang G, Xue X, et al. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer. 2013;12:81.
66. Xirouchakis E, Manousou P, Tsartsali L, Georgopoulos S, Burroughs AK. Insights into the pathogenesis of NAFLD: the role of metabolic and pro-inflammatory mediators. Ann Gastroenterol. 2009;22:24-33.
67. Quan HY, Kim DY, Kim SJ, Jo HK, Kim GW, Chung SH. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem Pharmacol. 2013;85:1330-40.
68. Sapp V, Gaffney L, EauClaire SF, Matthews RP. Fructose leads to hepatic steatosis in Zebrafish that is reversed by mechanistic target of Rapamycin (mTOR) inhibition. Hepatology. 2014;60:1581-92.
69. Yang J, Liu X, Yuan X, Wang Z. MiR-99b promotes metastasis of hepatocellular carcinoma through inhibition of claudin 11 expression and may serve as a prognostic marker. Oncol Rep. 2015;34:1415-23.
70. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 2011;120:183-93.
71. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ, et al. MiR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 2011;117:2842-52.
72. Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, et al. MiR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 2015;34:3240-50.
73. Poenitzsch Strong AM, Setaluri V, Spiegelman VS. MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. Arch Biochem Biophys. 2014;563:118-24.
74. Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG, et al. MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer. 2014;14:200.
75. Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351:85-98.
76. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients. J Cancer. 2014;5:103-14.
77. Summerer I, Unger K, Braselmann H, Schuettrumpf L, Maihoefer C, Baumeister P, et al. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients. Br J Cancer. 2015;113:76-82.
78. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:768-74.
79. Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, Malapelle U, et al. Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. Biomed Res Int. 2014;2014:840921.
80. Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, et al. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 2013;5:1639-42.
81. Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, et al. MiR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis. 2014;35:469-78.
82. Wang X, Kuang Y, Shen X, Zhou H, Chen Y, Han Y, et al. Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour Biol. 2015;36:719-27.
83. Wang G, Mao W, Zheng S, Ye J. Epidermal growth factor receptor-regulated miR-125a-5p - a metastatic inhibitor of lung cancer. FEBS J. 2009;276:5571-8.
84. Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X, et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer. 2010;10:318.
85. Yang Y, Li X, Yang Q, Wang X, Zhou Y, Jiang T, et al. The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogen. 2010;200:127-33.
86. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with Trastuzumab. Clin Cancer Res. 2011;17:2725-33.
87. Hsieh TH, Hsu CY, Tsai CF, Long CY, Chai CY, Hou MF, et al. MiR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget. 2015;6:494-509.
88. Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. MicroRNA profile of poorly differentiated thyroid carcinomas-new diagnostic and prognostic insights. J Mol Endocrinol. 2014;52(2):181-9.
89. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. 2013;57:1055-67.
90. Kiran S, Anwar T, Kiran M, Ramakrishna G. Sirtuin 7 in cell proliferation, stress and disease: rise of the Seventh Sirtuin! Cell Signal. 2015;27:673-82.
91. Hu Z, Shen WJ, Kraemer FB, Azhar S. MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells. Mol Cell Biol. 2012;32:5035-45.
92. Simionescu N, Niculescu LS, Sanda GM, Margina D, Sima AV. Analysis of circulating microRNAs that are specifically increased in hyperlipidemic and/or hyperglycemic sera. Mol Biol Rep. 2014;41:5765-73.
93. Zheng J, Zhou Z, Xu Z, Li G, Dong P, Chen Z, et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases correlates with disease progression. Mol Med Rep. 2015;12(1):1584-90.
94. Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 2012;12:227.
95. Wang C, Ren R, Hu H, Tan C, Han M, et al. MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chin J Cancer Res. 2014;26:17-29.
96. Wang TH, Yeh CT, Ho JY, Ng KF, Chen TC. OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting EphrinA5 in hepatocellular carcinoma. Mol Carcinog. 2015;8.
97. Leung WK, He M, Chang AW, Law PT, Wong N. Wnt/beta-catenin activates miR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett. 2015;362(1):97-105.
98. Leti F, Malenica I, Doshi M, Courtright A, Van Keuren-Jensen K, Legendre C, et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res. 2015;166:304-14.